Chromatide, an IP-driven company providing specialised synthesis and purification products and services to a broad spectrum of the chemical, pharmaceutical and biotechnology industries, is delighted to announce Clare Hildred has recently been appointed to the role of Chief Executive Officer.
Clare, a highly experienced Biotechnology executive, has a track record of delivering value and business change in high growth customer focused organisations. Previously she was Finance and Business Improvement Director at Avecia Biotechnology where she was involved in major contract negotiations, leading operational change projects and where she held senior financial management positions. Her background includes over seventeen years post qualification experience in high value business management and business development roles. She has a degree in Mathematics from Liverpool University and trained as a Chartered Accountant with Price Waterhouse Coopers. She subsequently spent five years with GEC, in an Engineering Project Management and Consultancy subsidiary, where she was Divisional Chief Accountant, before joining the Zeneca Plc / Avecia group.
Commenting on the announcement, Clare said, “I am very pleased to be joining Chromatide and to have the opportunity to lead an organisation that is looking to drive value from a rapidly expanding Intellectual Property Portfolio. I am looking forward to being part of the organisation’s continued growth and to overseeing the further development and commercialisation of the Company’s novel technologies which have been designed to improve biomolecule manufacturing processes”.
Dr Don Wellings, Chromatide’s CSO, added, “We are delighted to welcome Clare to Chromatide in her new role as Chief Executive Officer and look forward to working with her in developing the business and delivering on our key objectives.” He added, “Her strong finance background, commercial astuteness and experience in leading change to deliver major business improvements in a life science based organisation such as Avecia Biotechnology will be invaluable experience as Chromatide continues it’s growth strategy”.
For further information please contact: Chromatide Limited; Clare Hildred, Chief Executive Officer Officer; +44 (0)7710 387256; info@chromatide.com; www.chromatide.com
